The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Compound

retatrutide

Triple GIP, GLP-1 and glucagon receptor agonist; phase 3 ongoing.

36 topics 12 solved Synonyms: reta Group: Compound

Related in this group: semaglutide · tirzepatide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues

36 topics · page 1 of 2

TopicParticipantsRepliesViewsActivity
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold?
Asking directly, because I could not find a straight answer: What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? An honest uncertainty about TRIUMPH rather than a…
DNSLITNCAS+43 47 5.5k just now
Receptor desensitisation as a tolerance hypothesis, and its weak evidence
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on receptor…
MAVSOVSKMP+52 57 25k just now
What TRIUMPH is designed to answer, and why we should not pre-empt it
What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. TRIUMPH keeps being re-asked here and I think…
NNRNCIHBEK+4 8 142 6h
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. A methods question rather than a substantive…
HFITVAKLV+10 14 8.4k 16h
GIP receptor agonism and the argument about direction — does this still hold?
GIP receptor agonism and the argument about direction — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. A question about GIP receptor agonism…
HMBNSCPWEL+10 14 15k 16h
Why retatrutide discussion here is more cautious than elsewhere — one year on
Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Two things I would like separated before anyone answers on…
DBHCNRKKI+92 97 3.6k 20h
Retatrutide mass and identity: what a report should show
Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. The question about retatrutide mass and identity that I actually…
NTTKNECCYM+22 27 872 22h
GLP-1 receptor distribution: central and peripheral
Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. I have spent a fortnight trying to pin GLP-1 receptor distribution…
KHBPJNNSNH+90 98 30k 22h
Follow-up: The retatrutide phase 2 obesity paper, read closely
The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. A follow-up question about retatrutide phase 2 obesity paper that I did not know to…
JBZOCRJATV+19 23 16k 2d
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction
The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it. I would like to disagree…
CWMHRSOBRZ+43 47 19k 2d
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. The question about…
EHSBBOARB+3 7 1k 2mo
Why retatrutide discussion here is more cautious than elsewhere
Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. A question about retatrutide discussion that I think…
DSCAKNKN+7 12 7.7k 2mo
Amylin receptor signalling and satiety — what changed since
On the subject in the title: Amylin receptor signalling and satiety — what changed since Working notes rather than a conclusion. What changes if the standard account of Amylin receptor signalling and satiety…
GCCNRCBPB+73 78 3.5k 2mo
GLP-1 receptor distribution: central and peripheral — one year on
GLP-1 receptor distribution: central and peripheral — one year on — setting out what I have, and where I think it stops being reliable. An honest uncertainty about GLP-1 receptor distribution rather than a…
GRECSVTTTV+7 11 43k 3mo
Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version
Posting this under the heading it deserves: Receptor desensitisation as a tolerance hypothesis, and its weak evidence — the long version Everything below is what sits behind that. A narrow question about…
LRAAEVDMA+57 63 1k 6mo
Retatrutide's phase 2 heart-rate signal and how to think about it
On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a…
MVBERMBJER+19 23 20k 7mo
Follow-up: Glucagon receptor agonism in a weight-loss compound
Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about Glucagon receptor agonism that I did not know…
AMHNDNLAMD+5 9 21k 7mo
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper
Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about Retatrutide phase 2 in type that I did…
CDBNVSRAKF+1 5 31k 8mo
Revisiting: GLP-1 receptor distribution: central and peripheral
Revisiting: GLP-1 receptor distribution: central and peripheral — setting out what I have, and where I think it stops being reliable. An honest uncertainty about GLP-1 receptor distribution rather than a…
RTHFDTIBRM+61 66 15k 8mo
Follow-up: Why appetite effects are mostly central
Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A follow-up question about appetite effects that I did not know to ask the first time. The earlier thread…
CRRWMHKMN+86 90 61k 9mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Glucagon receptor…
AWNGNSPPRZ 4 3.7k 10mo
Second pass at: Triple agonism: additive, synergistic, or neither?
Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. Posting a small dataset on Triple agonism. It is…
KHALBDSBBO+114 120 1.4k 10mo
GIP receptor agonism and the argument about direction
GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. A question about GIP receptor agonism that I think has a definite answer, unlike…
ACQZES 2 867 10mo
[2026 update] What we do not know about retatrutide, listed explicitly
What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post, because a question…
FWCFATKCKB+79 83 952 11mo
Vagal afferents and the gut-brain pathway — one year on
Vagal afferents and the gut-brain pathway — one year on Writing it up because I had to work it out twice and would rather nobody else did. An honest uncertainty about Vagal afferents rather than a disguised…
AKTLAW 2 136 11mo
Triple agonism: additive, synergistic, or neither?
The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Asking about triple agonism on behalf of the question I keep…
EKEPAKTWJD+71 80 38k 11mo
Retatrutide phase 2 in type 2 diabetes: the Lancet paper
On the subject in the title: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Working notes rather than a conclusion. Asking about retatrutide phase 2 in type on behalf of the question I keep seeing…
SVDSNBOOMP+12 16 50k 12mo
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. Vagal afferents — I have the observation and I do not trust my interpretation of it, so I am…
KRBSKSBCD+5 9 44k 13mo
Second pass at: Retatrutide mass and identity: what a report should show
Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
CBTNNAFEKK+65 71 4.6k 13mo
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. An honest uncertainty about retatrutide dose escalation rather than a…
RMCCYMRMJW+149 159 30k 15mo